
    
      This is a phase 3, randomized, double-blind, placebo-control global study. The purpose of
      this study is to compare the effect of quizartinib versus placebo (administered with standard
      induction and consolidation chemotherapy, then administered as continuation therapy for up to
      36 cycles) on event-free survival in subjects with FLT3-internal tandem duplication (ITD)
      positive AML.
    
  